Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Citius Oncology, Inc. (CTOR) had Stock-Based Compensation of $3.90M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-7.74M |
|
-- |
|
-- |
|
$7.47M |
|
$-7.47M |
|
-- |
|
$-7.47M |
|
$-7.47M |
|
$-7.74M |
|
$-7.74M |
|
$-7.74M |
|
$-7.74M |
|
$-7.47M |
|
$-7.47M |
|
71.55M |
|
71.55M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$18.04M |
|
-- |
|
$73.40M |
|
$91.44M |
|
$49.74M |
|
$3.80M |
|
$6.06M |
|
$55.80M |
|
$35.64M |
|
$35.64M |
|
$35.64M |
|
71.55M |
|
| Cash Flow Statement Financials | |
$0.00M |
|
-- |
|
-- |
|
$0.00M |
|
$0.00M |
|
$0.00M |
|
|
Stock-Based Compensation |
$3.90M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.36 |
|
-- |
|
-- |
|
0.10 |
|
0.25 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-21.70% |
|
-21.70% |
|
-8.46% |
|
-19.61% |
|
$0.50 |
|
-- |
|
-- |
|